Litcius/Paper detail

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaqian Yang, Jihong Liu, Junke Wang, Lingying Wu, Z.L. Liu, Yunong Gao, Dongsheng Wang, Ge Lou, Haizhen Yang, Qi Zhou, Beihua Kong, Yi Huang, L.P. Chen, Guangyao Li, Rui An, K. Wang, Yu Zhang, Xiaojian Yan, Xin Lu, Weiguo Lü, Min Hao, Lai Wang, Heng Cui, Qingmei Chen, Guzhalinuer Abulizi, Xianghua Huang, Xusheng Tian, Hao Wen, C. Zhang, Jianmei Hou, Mansoor Raza Mirza

2021Annals of Oncology206 citationsDOI

Topics & Concepts

MedicineHazard ratioPlaceboInternal medicineClinical endpointOvarian cancerRandomizationChemotherapyPopulationProgression-free survivalRandomized controlled trialGastroenterologySurgeryConfidence intervalCancerPathologyAlternative medicineEnvironmental healthPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentLung Cancer Research Studies